Elevance Health, Inc. $ELV Shares Acquired by Vest Financial LLC

Vest Financial LLC boosted its holdings in Elevance Health, Inc. (NYSE:ELV) by 7.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 60,888 shares of the company’s stock after purchasing an additional 4,261 shares during the quarter. Vest Financial LLC’s holdings in Elevance Health were worth $23,674,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the business. Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Elevance Health in the second quarter valued at approximately $2,086,000. Stoneridge Investment Partners LLC bought a new position in Elevance Health during the 2nd quarter worth $970,000. State Street Corp increased its stake in Elevance Health by 1.3% during the 2nd quarter. State Street Corp now owns 10,426,610 shares of the company’s stock worth $4,032,283,000 after acquiring an additional 137,914 shares during the period. State of Wyoming bought a new position in Elevance Health during the 2nd quarter worth $1,765,000. Finally, Farther Finance Advisors LLC raised its holdings in Elevance Health by 27.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 11,826 shares of the company’s stock valued at $4,598,000 after acquiring an additional 2,518 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

NYSE ELV opened at $445.85 on Friday. The firm’s 50 day simple moving average is $407.53 and its 200 day simple moving average is $390.54. The firm has a market capitalization of $96.69 billion, a price-to-earnings ratio of 14.30, a P/E/G ratio of 2.12 and a beta of 0.70. The company has a current ratio of 1.47, a quick ratio of 1.52 and a debt-to-equity ratio of 0.68. Elevance Health, Inc. has a 1 year low of $274.84 and a 1 year high of $450.69.

Elevance Health (NYSE:ELV) last announced its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 EPS for the quarter, beating the consensus estimate of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The business had revenue of $50.44 billion during the quarter, compared to the consensus estimate of $49.28 billion. During the same period in the previous year, the business earned $6.03 earnings per share. The company’s revenue was up .7% on a year-over-year basis. As a group, research analysts expect that Elevance Health, Inc. will post 29.00 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Stockholders of record on Friday, December 4th will be paid a $1.72 dividend. The ex-dividend date is Friday, December 4th. This represents a $6.88 annualized dividend and a dividend yield of 1.5%. Elevance Health’s dividend payout ratio (DPR) is presently 30.58%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ELV shares. Robert W. Baird upped their target price on Elevance Health from $393.00 to $406.00 and gave the company a “neutral” rating in a research report on Thursday. Cantor Fitzgerald raised their price target on Elevance Health from $400.00 to $450.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 7th. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Leerink Partners boosted their price target on Elevance Health from $364.00 to $395.00 and gave the company a “market perform” rating in a research note on Friday, July 17th. Finally, Raymond James Financial set a $450.00 price objective on shares of Elevance Health in a research report on Tuesday, July 7th. Fifteen analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, Elevance Health currently has a consensus rating of “Moderate Buy” and an average price target of $450.29.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Strong Q3 earnings beat: Adjusted earnings were $6.99 per share, well above the roughly $4.71 analyst consensus and up from $6.03 a year earlier. Revenue of $50.44 billion also exceeded estimates of $49.28 billion, supported by stronger execution across Elevance’s businesses. Elevance Health Reports Third Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: Higher earnings outlook: Management raised its 2026 adjusted EPS baseline to at least $26.75, with some coverage citing a target of at least $29, and reiterated expectations for at least 12% adjusted EPS growth in 2027 from the higher baseline. Better medical-cost management and disciplined expenses support the upgraded forecast. Elevance lifts 2026 profit forecast on better medical cost management
• Positive Sentiment: Carelon provides growth potential: Carelon’s expansion helped offset pressure in the insurance business. Its cancer program reportedly reduced avoidable inpatient admissions by 15%, while the company sees continued demand for integrated healthcare services. Elevance also appointed Jeff Park as Carelon president, effective December 1, to lead its next growth phase. Elevance Health Names Jeff Park President of Carelon
• Positive Sentiment: Analyst support and shareholder return: Morgan Stanley raised its price target to $449 while retaining an Equal Weight rating. Elevance also declared a quarterly dividend of $1.72 per share, or $6.88 annualized, representing a yield of approximately 1.6%.
• Neutral Sentiment: Valuation has become more demanding: Robert W. Baird raised its target to $406 but kept a Neutral rating, implying limited upside from the recent trading level. The stock has also reached a 52-week high, which may limit near-term gains without additional earnings upgrades.
• Negative Sentiment: Underlying profitability risks remain: Medicaid margins and declining medical membership continue to weigh on Elevance’s Health Benefits segment. While medical-cost trends improved, nine-month operating gain declined, raising questions about how durable the earnings recovery will be. Elevance Health: Better Results, But Not Enough To Buy

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a diversified health benefits company that provides health insurance and related services in the United States. Its offerings serve employers, individuals and families, as well as members of government-sponsored programs, including Medicare and Medicaid. The company provides medical, pharmacy, behavioral health and other benefits through a range of health plans and specialty products.

Elevance Health operates its health benefits businesses through a portfolio that includes Blue Cross and Blue Shield-affiliated plans and other insurance offerings.